[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370113-105":59,"doc-detail-370113-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ntrk1-3-fusions-in-sarcomas-prevalence-significance-and-clinical-implications-a-systematic-review","NTRK1-3 fusions in sarcomas - prevalence, significance, and clinical implications - a systematic review","","The study reviews gene fusions involving Neurotrophic Receptor Tyrosine Kinase (NTRK) genes 1–3 and their clinical relevance in sarcomas. The work examines how advanced molecular testing can identify NTRK1-3 fusions and enable personalized treatment using TRK inhibitors. A comprehensive database search (PubMed/MEDLINE, SCOPUS, Web of Science) extracted study and molecular characteristics as well as clinical outcomes. Narrative and thematic synthesis, together with study quality assessment using the MASTER scale, combined results across 136 studies and 18,077 patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ntrk1-3-fusions-in-sarcomas-prevalence-significance-and-clinical-implications-a-systematic-review/370113/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ntrk1-3-fusions-in-sarcomas-prevalence-significance-and-clinical-implications-a-systematic-review/370113.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are NTRK1-3 fusions and why do they matter in sarcomas?","Question",{"text":113,"@type":114},"NTRK1-3 fusions can cause overexpression of TRK proteins, which drives tumor growth. The review emphasizes their clinical importance for selecting targeted therapy.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How often do NTRK1-3 fusions occur in sarcomas, and which fusions are most common?",{"text":118,"@type":114},"The review finds NTRK1-3 fusions are rare in sarcomas. Most positive cases involve NTRK1 and NTRK3 (about 93%), with ETV6-NTRK3 reported most frequently.",{"name":120,"@type":111,"acceptedAnswer":121},"How effective are TRK inhibitors like larotrectinib and entrectinib?",{"text":122,"@type":114},"Larotrectinib showed an 83.80% response rate with low mortality (2.82%) and recurrence (2.11%). Entrectinib had a lower response rate of 63.64%.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},370113,1790621726,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","FUTURE ONCOLOGY  \n2025, VOL. 21, NO. 30, 4011–4024  \n[https://doi.org/10.1080/14796694.2025.2597405](https://doi.org/10.1080/14796694.2025.2597405)  \nSYSTEMATIC REVIEW     \nNTRK1-3 fusions in sarcomas: prevalence, significance, and clinical implications – a systematic review  \nShahd Hamrana, Zaineh Alnoubania, Aly Mostafa Hassana, Amani A. Al-Rajhia, Humam Emad Rajhaa, Munirah Altaissana, Giridhara R. Babua, Zoran Gatalicab and Semir Vranića  \naCollege of Medicine, QU Health, Qatar University, Doha, Qatar; bPathology, Reference Medicine, Phoenix, AZ, USA  \nABSTRACT  \nAim: Gene fusions involving Neurotrophic Receptor Tyrosine Kinase (NTRK) genes lead to Tropomyosin Receptor Kinases (TRK) overexpression. Detecting NTRK1-3 fusions through advanced molecular techniques has revolutionized cancer care through personalized medicine, such as TRK inhibitors. Methods: We conducted a comprehensive search of databases (PubMed/MEDLINE, SCOPUS, Web of Science) and extracted data on study characteristics, molecular characteristics, and clinical outcomes. Data synthesis involved narrative and thematic analysis and study quality assessment using the Methodological Standard for Epidemiological Research (MASTER) scale.  \nResults: We included 136 studies with 18,077 patients. The most common tumor categories were unclassified soft tissue sarcomas (11.09%), gynecological sarcomas (5.64%), and liposarcomas (3.37%) . Most tumors were gynecologic (5.64%), followed by the limbs (1.45%) . Genomic sequencing was the predominant diagnostic method used in 110 studies. Overall, 551 patients with sarcoma tested positive for NTRK1-3 gene fusions, primarily involving NTRK1 and NTRK3 (~93%), with ETV6-NTRK3 fusion being the most frequently reported fusion. Larotrectinib was used in 142 patients, demonstrating an 83.80% response rate, with low mortality (2.82%) and recurrence (2.11%) rates. Entrectinib had a lower response rate of 63.64% .  \nConclusions: We confirm the rarity of NTRK1-3 fusions in sarcomas. TRK inhibitors show high efficacy in sarcomas, emphasizing the necessity of genomic testing in all cases.  \nProtocol registration: [https://www.crd.york.ac.uk/PROSPERO/view/CRD42024563594](https://www.crd.york.ac.uk/PROSPERO/view/CRD42024563594) .  \nPLAIN LANGUAGE SUMMARY  \nUnderstanding NTRK1-3 Change In Sarcoma And How New Medicines Help  \nSarcomas are rare cancers that can grow in soft tissues, muscle, fat, or bone. In a small number of these cancers, a change in genes, called Neurotrophic Receptor Tyrosine Kinases (NTRK1-3), occurs. The change is called fusion, in which a part of one gene joins the part of another gene. This change keeps a signal in the body switched on that tells the cancer to grow.  \nDoctors now use a group of medicines called TRK inhibitors for cancers with NTRK1-3 fusions. These drugs are different from chemotherapy. Instead of affecting the whole body, they target cancer cells with this gene change, which means they often cause fewer side effects.  \nIn this review, we looked at all published studies to learn how often NTRK1-3 fusions appear in sarcomasand how patients respond to TRK inhibitors. We found that NTRK1-3 fusions are rare in sarcomas, but when they are present, patients often respond well to medicines like larotrectinib and entrectinib. Many patients had their tumors shrink, and some had no sign of cancer after treatment. Most patients handled the medicines well, with only mild side effects.  \nSome patients had the cancer come back because the tumor developed new changes that made the drug not work. This review shows that testing for NTRK1-3 gene fusions is important. If we find this change, patients can receive targeted treatment that may be more effective and easier to tolerate than standard treatment. More studies are still needed to understand how long these benefits last.  \nARTICLE HISTORY  \nReceived 25 June 2025 Accepted 26 November 2025  \nKEYWORDS  \nSoft tissue tumors;  \nSarcomas; NTRK1-3 fusions; TRK inhibitors; s","cbCailJ6YaHbxGGm","https://ap.wps.com/l/cbCailJ6YaHbxGGm","pdf",2859641,14,"English","# Introduction\n# Methods\n# Results\n# Conclusions\n# Protocol registration\n# Plain language summary\n# Article highlights","[{\"question\":\"What are NTRK1-3 fusions and why do they matter in sarcomas?\",\"answer\":\"NTRK1-3 fusions can cause overexpression of TRK proteins, which drives tumor growth. The review emphasizes their clinical importance for selecting targeted therapy.\"},{\"question\":\"How often do NTRK1-3 fusions occur in sarcomas, and which fusions are most common?\",\"answer\":\"The review finds NTRK1-3 fusions are rare in sarcomas. Most positive cases involve NTRK1 and NTRK3 (about 93%), with ETV6-NTRK3 reported most frequently.\"},{\"question\":\"How effective are TRK inhibitors like larotrectinib and entrectinib?\",\"answer\":\"Larotrectinib showed an 83.80% response rate with low mortality (2.82%) and recurrence (2.11%). Entrectinib had a lower response rate of 63.64%.\"}]","NTRK1-3 fusions in sarcomas - prevalence, significance, and clinical implications - a systematic review | PDF",1790186772,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee3668789e4ad67c1d28f232f8370a4a.webp",983,1280,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/915d52ab0b7c1ceff44d7f4ec9fe663a.webp",982,1278,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/873ff336d266ff883a0ce35b7e15a6b9.webp",981,1277,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d3d4978d174c67035a10b40051fc430.webp",980,1276]